This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pacira Pharmaceuticals Inc (PCRX)

NASDAQ: Health Care

$65.06 +0.13 | 0.20%
11/27/15 - 10:49:04 AM ET (BATS BZX Real-time Price)
  • Prev Close: 64.93
  • Day's Open: 65.20
  • Volume: 112.55K
  • Avg Vol: 1.05M
  • Shares Outstanding: 36.76M
  • Mkt Cap: 2.39B
  • Div: --
  • Div Yield: --
  • P/E: 231.89
  • EPS: -0.39
PCRX Day's Range
PCRX 52 Week Range
PCRX Business Summary
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States.View PCRX key stats
Pacira Pharmaceuticals Inc - PCRX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Pacira Pharmaceuticals Inc as a Hold with a ratings score of C.
Report Snippet: We rate PACIRA PHARMACEUTICALS INC (PCRX) a HOLD. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow.
Rating: 2.67 out of 5, 'C' Hold.
You can view the full analysis from the report here:
PCRX Rating Report
PCRX Performance as of Prev. Close
PCRX EPS Performance
1-Yr Ago
2-Yrs Ago
3-Yrs Ago
PCRX Percentage in these ETFs

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

PCRX Pacira Pharmaceuticals Inc

Chart of PCRX

Analysts Ratings for PCRX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

PCRX Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs